Clinical Trials Logo

Osteoporosis clinical trials

View clinical trials related to Osteoporosis.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03770338 Not yet recruiting - Osteoporosis Clinical Trials

Preoperative Teriparatide Use on Insertional Torque of Pedicle Screws for Lumbar Fusion Surgery

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

This project aims to investigate any difference of insertional torque strength for osteoporotic patients with preoperative 1-month teriparatide injections versus those without. The increased insertional torque of pedicle screws during surgery after only 1 month of teriparatide use has also been studied. However, the effect of teriparatide on vertebral body bone mineral density (BMD) prior to and after fusion surgery has not been studied. The effects on screw insertional torque has also not been studied via a randomized controlled trial method.

NCT ID: NCT03747289 Not yet recruiting - Osteoporosis Clinical Trials

Comparison of a Weight Bearing and a Non-weight Bearing Protocol on Osteoporotic Women With Chronic Low Back Pain

Start date: December 2018
Phase: N/A
Study type: Interventional

The effect of exercising in different body positions on bone growth in osteoporotic women is known, but its effect on their function, low back pain, lumbar range of motion and quality of life remains unknown. Therefore, the investigators plan to make a comparison of the effect of a weight bearing protocol and a non-weight bearing protocol on osteoporotic women with chronic low back pain. 40 women with osteoporosis and low back pain will be divided into two groups. Each group will be given a specific exercise protocol, twice a week for four weeks, 45 minutes each time. The participants will be tested before starting the program, immediately after finishing it and again two months later. The tests will include filling out the Roland Morris Disability Questionnaire, the SF-36 quality of life Questionnaire, pain measurement by VAS (Visual Analogue Scale) and lumbar range of motion measurement by a digital Inclinometer. Statistical analysis will be made in order to compare the dependent variables between groups.

NCT ID: NCT03742362 Not yet recruiting - Clinical trials for Osteoporosis, Postmenopausal

MRI Study of the Distal Radius Bone Marrow Fat Fraction in Osteoporotic and Healthy Women

Start date: November 15, 2018
Phase: N/A
Study type: Interventional

The aim of the study is to test whether the distal radius bone marrow show significant difference in the fat fraction in young women compared to post menopausal women with and without osteoporosis.

NCT ID: NCT03730207 Not yet recruiting - Clinical trials for Pathological Fracture of Vertebra Due to Secondary Osteoporosis (Disorder)

Xpede Clinical Study

Start date: December 2018
Phase: N/A
Study type: Interventional

The purpose of this clinical study is to confirm the efficacy and safety of the Kyphon®Xpede™ Bone Cement in human use in China.

NCT ID: NCT03683849 Not yet recruiting - Osteoporosis Clinical Trials

Dancing Against Fall Fractures in Osteoporosis Patients and Healthy Elderly

Start date: October 1, 2018
Phase: N/A
Study type: Interventional

This study evaluates physiological measurements and their role in among falls in healthy elderly (65yr or older) or elderly suffering from osteoporosis. The study further seeks to evaluate if dancing can be used as training for preventing falls.

NCT ID: NCT03623633 Not yet recruiting - Osteoporosis Clinical Trials

Comparative Antiresorptive Efficacy Discontinuation of Denosumab

Start date: September 1, 2018
Phase: Phase 4
Study type: Interventional

Osteoporosis remains a significant healthcare burden for the United States. Current FDA-approved osteoporosis treatments include teriparatide, abaloparatide, bisphosphonates, denosumab, and raloxifene. Denosumab is a fully human monoclonal antibody that specifically binds to receptor activator of nuclear factor kappa-B ligand (RANKL). Denosumab potently suppresses osteoclastic activity but bone turnover rapidly normalizes and bone turnover marker levels can rebound above baseline levels after the drug is discontinued. The proposed study will help us determine the relative efficacy of two oral antiresorptive medications that are FDA-approved for treatment of postmenopausal osteoporosis (alendronate and raloxifene) in preventing the rebound increase in bone turnover that occurs after denosumab discontinuation.

NCT ID: NCT03563235 Not yet recruiting - Clinical trials for Postmenopausal Osteoporoses

Clinical Study on Treatment of Postmenopausal Osteoporosis (Kidney Deficiency and Blood Stasis Syndrome) With Xulin Jiangu Granules

CSOPOPWXJG
Start date: September 1, 2018
Phase: Early Phase 1
Study type: Interventional

Osteoporosis is a common senile disease with a high incidence. The Chinese medicine differentiation treatment has small side effects and can be taken for a long time, which has certain advantages. This project adopts the experience of the person in charge of the project-Xulin Jiangu Granules and clinically collects patients with postmenopausal osteoporosis (kidney deficiency and blood stasis syndrome).

NCT ID: NCT03534934 Not yet recruiting - Osteoporosis Clinical Trials

CT-Based Modeling of Bone Micro-Architecture and Fracture-Risk in COPD

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

The goal of this translational study is to establish a newly emerging CT-based tool for the characterization of changes in bone micro-architecture and assessment of their implications for fracture-risk in a population of COPD patients at risk for osteoporosis. The tool will be suitable and generalizable across emerging CT scanners from different vendors, and it will provide a more structurally-based assessment of osteoporosis and bone loss than is provided by simple bone density measures. The study will characterize the impact of different COPD-related factors on bone structure, and their implications for fracture-risk, leading to the development of a COPD-specific model for assessment of fracture-risk that will utilize patient-specific demographic, clinical and radiographic data, and CT BMD at the spine, as well as bone structural measures at the hip and/or ankle.

NCT ID: NCT03518268 Not yet recruiting - Breast Cancer Clinical Trials

Vivomixx for Prevention of Bone Loss in Women With Breast Cancer Treated With an Aromatase Inhibitor

Start date: October 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates the efficacy of the probiotic food supplement Vivomixx in the prevention of bone loss occurring in post menopausal women with breast cancer treated with an aromatase inhibitor. Half of the participants will receive Vivomixx while the other half will receive a placebo. The primary endpoint is to assess changes of bone turnover markers during the period of 6 months.

NCT ID: NCT03483584 Not yet recruiting - HIV Clinical Trials

Incidence of HANA Conditions in HIV-infected Individuals

Start date: April 6, 2018
Phase:
Study type: Observational

With the availability of effective anti-retroviral therapy, HIV-infected individuals are expected not to die of AIDS and have longer life expectancy. But at the same time, HIV-associated non-AIDS (HANA) conditions are becoming more important in their clinical management. It is currently uncertain whether patients started on different anti-retroviral regimens will have different incidence of HANA conditions. This study aims to evaluate the incidence of various HANA conditions in a cohort of newly diagnosed HIV-infected individuals in Hong Kong initiating anti-retroviral treatment. The incidence of various HANA conditions will be evaluated for those receiving INSTI versus other non-INSTI-based regimens. The HANA conditions evaluated will include 1. Hypertension 2. Diabetes and insulin resistance 3. Dyslipidemia 4. Lipodystrophy 5. Metabolic syndrome 6. Osteopenia and osteoporosis 7. Vitamin D deficiency 8. Renal impairment and kidney tubular dysfunction and 9. Liver fibrosis. Patients will be assessed prior to initiation of anti-retroviral therapy, and 48 weeks and 96 weeks after initiation of treatment. The incidence of development of each HANA condition will be determined and compared between those initiated different anti-retroviral regimens.